Suppression of cancer growth by nonviral gene therapy based on a novel reactive oxygen species-responsive promoter

Molecular Therapy

Volumn 17, Issue 8, 2009, Pages 1355-1364

  Policastro, Lucía L, ^a,b   Ibañez, Irene L ^a   Durán, Hebe A ^a,c   Soria, Gastón ^b   Gottifredi, Vanesa ^b   Podhajcer, Osvaldo L ^b  

^a DEPARTAMENTO DE FÍSICA   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c UNIVERSIDAD NACIONAL DE SAN MARTÍN   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DOXORUBICIN; EARLY GROWTH RESPONSE FACTOR 1; GANCICLOVIR; HYDROGEN PEROXIDE; LUCIFERASE; REACTIVE OXYGEN METABOLITE; THYMIDINE KINASE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INHIBITION; CELL LEVEL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; ELECTROPORATION; FEMALE; GAMMA IRRADIATION; GENE CONSTRUCT; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; GENETIC VARIABILITY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; NUCLEOTIDE SEQUENCE; PLASMID; PROMOTER REGION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; EARLY GROWTH RESPONSE PROTEIN 1; GANCICLOVIR; GENE THERAPY; HUMANS; HYDROGEN PEROXIDE; MELANOMA; MICE; MICE, NUDE; NEOPLASMS; PROMOTER REGIONS, GENETIC; THYMIDINE KINASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68249107275     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.103     Document Type: Article

References (49)

1. Valko, M, Leibfritz, D, Moncol, J, Cronin, MT, Mazur, M and Telser, J (2007). Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39: 44-84.
2. Jackson, AL and Loeb, LA (2001). The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 477: 7-21.
3. Halliwel, B (2007). Oxidative stress and cancer: Have we moved forward? Biochem J 401: 1-11.
4. Irani, K, Xia, Y, Zweier, JL, Sollott, SJ, Der, CJ, Fearon, ER et al. (1997). Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275: 1649-1652.
5. Arnold, RS, Shi, J, Murad, E, Whalen, AM, Sun, CQ, Polavarapu, R et al. (2001). Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci USA 98: 5550-5555.
6. Veal, EA, Day, AM and Morgan, BA (2007). Hydrogen peroxide sensing and signaling. Mol Cell 26: 1-14.
7. Laurent, A, Nicco, C, Chéreau, C, Goulvestre, C, Alexandre, J, Alves, A et al. (2007). Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 65: 948-956.
8. Shono, T, Ono, M, Izumi, H, Jimi, SI, Matsushima, K, Okamoto, T et al. (1996). Involvement of the transcription factor NF-kappaB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol Cell Biol 16: 4231-4239.
9. Kuroki, M, Voest, E, Amano, S, Beerepoot, L, Takashima, S, Tolentino, M et al. (1996). Reactive oxygen intermediates increased vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 98: 1466-1471.
10. Ushio-Fukai, M (2006). Redox signaling in angiogenesis: Role of NADPH oxidase. Cardiovasc Res 71: 226-235.
11. Wu, WS (2006). The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 25: 695-705.
12. Radisky, DC, Levy, DD, Littlepage, LE, Liu, H, Nelson, CM, Fata, JE et al. (2005). Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436: 123-127.
13. Nelson, KK, Ranganathan, AC, Mansouri, J, Rodriguez, AM, Providence, KM, Rutter, JL et al. (2003). Elevated sod2 activity augments matrix metalloproteinase expression: Evidence for the involvement of endogenous hydrogen peroxide in regulating metastasis. Clin Cancer Res 9 424-432.
14. Szatrowski, TP and Nathan, CF (1991). Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51: 794-798.
15. Policastro, L, Molinari, B, Larcher, F, Blanco, P, Podhajcer, OL, Costa, CS et al. (2004). Imbalance of antioxidant enzymes in tumor cells and inhibition of proliferation and malignant features by scavenging hydrogen peroxide. Mol Carcinog 39: 103-113.
16. Toyokuni, S, Okamoto, K, Yodoi, J and Hiai, H (1995). Persistent oxidative stress in cancer. FEBS Lett 358: 1-3.
17. Evans, MD, Dizdaroglu, M and Cooke, MS (2004). Oxidative DNA damage and disease: Induction, repair and significance. Mutat Res 567: 1-61.
18. Al-Gayyar, MM, Eissa, LA, Rabie, AM and El-Gayar, AM (2007). Measurements of oxidative stress status and antioxidant activity in chronic leukaemia patients. J Pharm Pharmacol 59: 409-417.
19. Ko, D, Hawkins, L and Yu, DC (2005). Development of transcriptionally regulated oncolytic adenoviruses. Oncogene 24: 7763-7774.
20. Ido, A, Uto, H, Moriuchi, A, Nagata, K, Onaga, Y, Onaga, M et al. (2001). Gene therapy targeting for hepatocellular carcinoma: Selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res 61: 3016-3021.
21. Ballinger, JR (2001). Imaging hypoxia in tumor. Semin Nucl Med 31: 321-329.
22. Liu, H, Colavitti, R, Rovira, II and Finkel, T (2005). Redox-dependent transcriptional regulation. Circ Res 97: 967-974.
23. Schäfer, G, Cramer, T, Suske, G, Kemmner, W, Wiedenmann, B and Höcker, M (2003). Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J Biol Chem 278: 8190-8198.
24. Datta, R, Taneja, N, Sukhatme, VP, Qureshi, SA, Weichselbaum, R and Kufe, DW (1993). Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci USA 90: 2419-2422.
25. Minotti, G, Menna, P, Salvatorelli, E, Cairo, G and Gianni, L (2004). Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229.
26. Chen, J and Stubbe, J (2005). Bleomycins: Towards better therapeutics. Nat Rev Cancer 5: 102-112.
27. Scott, SD, Joiner, MC and Marples, B (2002). Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy. Gene Ther 9: 1396-1402.
28. Senzer, N, Mani, S, Rosemurgy, A, Nemunaitis, J, Cunningham, C, Guha, C et al. (2004). TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase I study in patients with solid tumors. J Clin Oncol 22: 592-601.
29. Marples, B, Scott, SD, Hendry, JH, Embleton, MJ, Lashford, LS and Margison, GP (2000). Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther 7: 511-517.
30. Hernandez-Alcoceba, R, Pihalja, M, Nunez, G and Clarke, MF (2001). Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells. Cancer Gene Ther 8: 298-307.
31. Modlich, U, Pugh, CW and Bicknell, R (2000). Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther 7: 896-902.
32. Greco, O, Marples, B, Dachs, GU, Williams, KJ, Patterson, AV and Scott, SD (2002). Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Ther 9: 1403-1411.
33. Guzy, RD and Schumacker, PT (2006). Oxygen sensing by mitochondria at complex III: The paradox of increased reactive oxygen species during hypoxia. Exp Physiol 91: 807-819.
34. Wagner, BA, Evig, CB, Reszka, KJ, Buettner, GR and Burns, CP (2005). Doxorubicin increases intracellular hydrogen peroxide in PC3 prostate cancer cells. Arch Biochem Biophys 440: 181-190.
35. Sanders, PM and Tisdale, MJ (2000). Role of lipid-mobilising factor (LMF) in protecting tumour cells from oxidative damage. Br J Cancer 90: 1274-1278.
36. Heller, LC, Ugen, K and Heller, R (2005). Electroporation for targeted gene transfer. Expert Opin Drug Deliv 2: 255-268.
37. Lucas, ML and Heller, R (2003). IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma. DNA Cell Biol 22: 755-763.
38. Li, S, Zhang, X and Xia, X (2002). Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy. J Natl Cancer Inst 94: 762-768.
39. Goto, T, Nishi, T, Kobayashi, O, Tamura, T, Dev, SB, Takeshima, H et al. (2004). Combination electro-gene therapy using herpes virus thymidine kinase and interleukin-12 expression plasmids is highly efficient against murine carcinomas in vivo. Mol Ther 10: 929-937.
40. Byrne, CM, Thompson, JF, Johnston, H, Hersey, P, Quinn, MJ, Michael Hughes, T et al. (2005). Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 15: 45-51.
41. Yuan, XM and Li, W (2003). The iron hypothesis of atherosclerosis and its clinical impact. Ann Med 35: 578-591.
42. Romero, JC and Reckelhoff, JF (1999). State-of-the-Art lecture. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 34: 943-949.
43. Firestein, GS, Echeverri, F, Yeo, M, Zvaifler, NJ and Green, DR (1997). Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 94: 10895-10900.
44. Cunnane, G, Fitzgerald, O, Beeton, C, Cawston, TE and Bresnihan, B (2001). Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum 44: 2263-2274.
45. Eriksson, JW (2007). Metabolic stress in insulin's target cells leads to ROS accumulation. A hypothetical common pathway causing insulin resistance. FEBS Lett 581: 3734-3742.
46. Emerit, J, Edeas, M and Bricaire, F (2004). Neurodegenerative diseases and oxidative stress. Biomed Pharmacother 58: 39-46.
47. Daud, AI, DeConti, RC, Andrews, S, Urbas, P, Riker, AI, Sondak, VK et al. (2008). Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26: 5896-5903.
48. Block, KI, Koch, AC, Mead, MN, Tothy, PK, Newman, RA and Gyllenhaal, C (2007). Impact of antioxidant supplementation on chemotherapeutic efficacy: A systematic review of the evidence from randomized controlled trials. Cancer Treat Rev 33: 407-418.
49. Alexandre, J, Batteux, F, Nicco, C, Chéreau, C, Laurent, A, Guillevin, L et al. (2006). Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer 119: 41-48.